Early Adopters and Customer Profiles

3min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

Roxanne Jones: What was it like in the early days to kind of scaling from you had this product. You know, rolling it out to an initial set of oncologists and then, you know, how did you kind of overcome that hurdle of now kind of getting dozens and then hundreds?Jones: We really focused on early days on early adopters profiling who they are or the people who are more receptive to innovative technologies. And once actually we got a regulatory body approval, guideline, inclusion, some reimbursement wins, then actually we passed through that chasm and mainstream people actually started using it still in diagnostic.

This week, we’re super excited to have AmirAli Talasaz, co-CEO and co-founder of Guardant Health, a leading precision oncology company focused on helping conquer cancer globally.

Founded in 2011, Guardant Health is focused on helping conquer cancer through the use of its proprietary blood-based tests, vast data sets and advanced analytics. Guardant’s solutions include treatment selection, recurrence detection and early detection of cancer. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum.

Through multiple rounds of private financing, Guardant Health raised over $500 million from investors including Sequoia, Khosla, Lightspeed, OrbiMed, and Softbank, and Pear! and Guardant completed a successful IPO in October 2018.